GP IIb/IIIa Inhibitors

Yale-New Haven Health System Designates Tirofiban as the Primary Glycoprotein IIb/IIIa Inhibitor

04/26/2017

Cath Lab Digest talks with Samuel S. Hahn, MD, FACC, FSCAI,
Associate Director, Cardiac Catheterization Laboratory; Associate Clinical
Professor of Medicine, Yale School of Medicine

Ralph J. Riello III, PharmD, BCPS, Cardiovascular Critical Care Pharmacist, Coronary Intensive Care Unit (CICU), Department of Pharmacy Services

Yale-New Haven Health System
New Haven, Connecticut

Cath Lab Digest talks with Samuel S. ...

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic...

04/26/2017

Cath Lab Digest

Challenges

A Case-Based Discussion of No-Reflow Treatment: Do We Need More?

04/05/2016

Kusum Lata, MD, Cindy Grines, MD, FSCAI, Amir Kaki, MD, FACC, FSCAI, Medical Director, Cardiac Catheterization Laboratories, Detroit Medical Center Cardiovascular Institute – Heart Hospital, Detroit, Michigan

Kusum Lata, MD, Cindy Grines, MD, FSC...

Herein, we present a case-based approach in order to discuss the available treatment of NR and to review the clinical significance of ventricular unloading.

Herein, we present a case-based...

04/05/2016

Cath Lab Digest